2023
CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma
Noble J, Locke F, Savid-Frontera C, Jain M, Turner J, Miranda J, Madanayake T, Naderinezhad S, Corallo S, Menges M, Reid K, Robinson T. CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma. Blood 2023, 142: 3506. DOI: 10.1182/blood-2023-185074.Peer-Reviewed Original ResearchNon-durable responseProgression free survivalSurface protein expressionB-cell acute lymphoblastic leukemiaCAR-TCAR-T treatmentFlow cytometryProtein expressionFree survivalCell linesWestern blottingRefractory diffuse large B-cell lymphomaMedian expressionChimeric antigen receptor T cellsJeKo-1Associated with progression free survivalDiffuse large B-cell lymphomaPre-treatment tumor biopsiesPre-treatment tumor samplesLarge B-cell lymphomaIntron 2CAR-T failureCD19 surface expressionR/R DLBCL patientsIntron 6
2018
Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel
Jain M, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Liu H, Falchook A, Robinson T, Kim S, Locke F. Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. Blood 2018, 132: 4220. DOI: 10.1182/blood-2018-99-117133.Peer-Reviewed Original ResearchCytokine release syndromeAxi-cel therapyCAR-T infusionCy conditioningCase seriesT infusionTumor burdenAxicabtagene ciloleucelCAR TSpeakers bureauRadiation therapyRefractory diffuse large B-cell lymphoma patientsRefractory diffuse large B-cell lymphomaChimeric antigen receptor T-cell therapyPatient experienced progressive diseaseSevere cytokine release syndromeDiffuse large B-cell lymphoma patientsDisease controlLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaAdvisory CommitteeLarge B-cell lymphomaCAR T cell efficacyExperienced progressive disease